Key Highlights

  • Consensus EPS of 1.20 compares with second-quarter adjusted EPS of 1.13 and GAAP diluted EPS of 1.24.
  • Consensus revenue of USD 5.35 billion compares with second-quarter revenue of USD 5,295 million, against USD 5,007 million.
  • Organic orders rose 11.1%, backlog reached USD 23.9 billion and book-to-bill was 1.15x in the second quarter.
  • Full-year guidance is organic revenue growth of 3% to 4% and adjusted EPS of 4.80 to 5.00.

GE HealthCare Technologies (NASDAQ:GEHC) reports third-quarter results on Wednesday, Oct. 28, before the market opens. Consensus stands at EPS of 1.20 on revenue of USD 5.35 billion, and the company has a market capitalization of USD 32.51 billion.

GE HealthCare Technologies reports Advanced Imaging Solutions, Pharmaceutical Diagnostics and Patient Care Solutions segments. Second-quarter revenue was USD 5,295 million against USD 5,007 million, and net income attributable to the company was USD 561 million against USD 486 million.

Estimates Against the Last Reported Quarter and Full-Year Guidance

The EPS estimate of 1.20 is above the adjusted EPS of 1.13 and below the GAAP diluted EPS of 1.24 reported for the second quarter, and the estimates table does not state its EPS basis. The revenue estimate of USD 5.35 billion is above the USD 5,295 million reported.

Management guided full-year organic revenue growth of 3% to 4%, an adjusted EBIT margin of 15.4% to 15.7%, adjusted EPS of 4.80 to 5.00 and free cash flow of approximately USD 1.6 billion.

What Management Guided and What It Left Open

Management put the full-year inflationary headwind from memory chips, oil and freight at USD 250 million and said equipment revenue was nearly 85% secured entering the third quarter. It said revenue has historically split about 48% in the first half and 52% in the second, and that its 2026 outlook is in line with that pattern.

Management left open the future of Patient Care Solutions, saying its review of strategic options covers continued ownership, a sale and other transactions. The transcript contains no third-quarter dollar guidance.

Segment Results and Orders

Organic revenue growth was 3.5%, and organic orders growth of 11.1% was the highest since the spin-off. Advanced Imaging Solutions organic revenue was USD 3,668 million, up 5.0%, with an EBIT margin of 13.9%. Pharmaceutical Diagnostics organic revenue was USD 835 million, up 14.6%, with an EBIT margin of 29.6%.

Patient Care Solutions organic revenue was USD 673 million, down 13.5%, and its EBIT was negative USD 26 million against USD 60 million. Adjusted EBIT margin was 14.2%, down 40 basis points, and adjusted EPS of 1.13 included USD 0.04 of tariff refunds.

GAAP Lines, Cash and Debt

Gross profit was USD 2,180 million against USD 1,985 million, and operating expenses were USD 1,441 million against USD 1,331 million, including research and development of USD 323 million against USD 302 million. Operating income was USD 739 million against USD 654 million, and income before income taxes was USD 693 million against USD 613 million.

Free cash flow was USD 68 million, including USD 107 million of tariff refunds, and the company repurchased 3.3 million shares for USD 200 million. Cash, cash equivalents and restricted cash were USD 2,105 million against USD 4,512 million at year-end, and long-term borrowings were USD 10,091 million against USD 9,495 million. The estimates table lists a market capitalization of USD 32.51 billion.

Items to Track in the Report

Adjusted EPS against 1.20 and revenue against USD 5.35 billion are the headline comparisons. Other markers are orders, backlog, Patient Care Solutions EBIT and the inflationary cost headwind.